Lung regeneration using amniotic fluid mesenchymal stem cells
Artificial Cells, Nanomedicine, and Biotechnology An International Journal
Alireza Azargoon & Babak Negahdari
Respiratory diseases, such as chronic obstructive pulmonary disease (COPD), pulmonary hypertension and lung fibrosis, are yet a major challenge in the world and they result in irreversible structural lung damage. Lung transplantation as the only therapeutic option face some major challenges like graft rejection and cancer, arising as a result of immunosuppression. A low survival rate faced by lung transplantation patients is presently limited to approximately 5 years. Lungs shortage therefore calls for a mechanism that would increase the availability of suitable organs for transplantation. In this review, we give an update on the use of amniotic fluid mesenchymal stem cells (AFMSCs) as an optimal source for lungs scaffold re-cellularization, due to their limitless accessibility and possibility for proliferation and differentiation. Further studies will be required in tissue engineering (TE) and regenerative medicine (RM), especially shifting our focus towards AFMSCs as a cell source for this regeneration.
Stem cell research had a significant progress during the past years and had turn out to be one the most attractive aspect of modern biology. Thanks to several studies, stem cells hold a significant valuable possibility in supporting and protecting native tissues throughout inflammatory and ischaemic-induced damage. AFMSCs hold a great potential. This review proposes AFMSCs to be a better source of stem cell for lungs regeneration because it has the ability to differentiate to all forms of cells; however, this stem cell choice needs further laboratory investigations.